GlassScriptPhysician profile
Poonam Duggal
NPI 1356386510
$3,827.57
in general payments reported to CMS, 2019-2025
25 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $717 · 2021: $365 · 2022: $514 · 2023: $318 · 2024: $481 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $784.70 | 2020-2025 | Airsupra, Breztri, Tezspire |
| Pfizer INC. | $478.49 | 2019-2025 | |
| Novo Nordisk INC | $401.18 | 2020-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $359.17 | 2020-2025 | Zepbound, Mounjaro |
| Corcept Therapeutics | $274.57 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $273.07 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $219.05 | 2022-2024 | Tezspire, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $139.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.51 | 2019-2025 | Ofev, Jardiance |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.06 | 2023-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $99.97 | 2019 | |
| Exact Sciences Corporation | $90.22 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $66.29 | 2019-2024 | |
| Abbvie INC. | $63.91 | 2021-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $31.90 | 2025 | Rexulti |
| Nevro Corp. | $29.54 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $28.54 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.18 | 2020-2021 | |
| Allergan, INC. | $18.66 | 2020 | |
| Silk Road Medical, INC. | $17.62 | 2019 | |
| Hologic Sales and Service, LLC | $16.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.14 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.70 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.54 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Duggal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.